AI Article Synopsis
- Mucormycosis is an invasive fungal infection caused by fungi from the Mucoraceae family, notably Rhizopus, Rhizomucor, and Cunninghamella.
- The disease primarily affects individuals with underlying health issues like uncontrolled diabetes, renal failure, or those who are immunocompromised.
- The case presented involves a patient who developed a mixed infection of Mucormycosis and Aspergillosis after maxillofacial trauma, treated through both medical and surgical interventions.
Article Abstract
An invasive fungal infection caused by saprophytic and aerobic fungi Rhizopus, Rhizomucor, and Cunninghamella genera of the family Mucoraceae is known as Mucormycosis. Typically, Mucormycosis manifests in patients with conditions like uncontrolled diabetes, renal failure, patients receiving chemotherapy, long term steroid therapy or patients who are immunocompromised such as Acquired Immuno Deficiency Syndrome. The authors report a case of mixed opportunistic fungal infection of Mucormycosis and Aspergillosis following maxillofacial trauma that was treated by both medical and surgical line of management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899331 | PMC |
| http://dx.doi.org/10.1007/s12070-023-03492-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Performance of Chest CT-Based Artificial Intelligence Models in Distinguishing Pulmonary Mucormycosis, Invasive Pulmonary Aspergillosis, and Pulmonary Tuberculosis.
Med Mycol
January 2025
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
In clinical practice, differentiating among pulmonary mucormycosis (PM), invasive pulmonary aspergillosis (IPA), and pulmonary tuberculosis (PTB) can be challenging. This study aimed to evaluate the performance of chest CT-based artificial intelligence (AI) models in distinguishing among these three diseases. Patients with confirmed PM, IPA, or PTB were retrospectively recruited from three tertiary hospitals.
View Article and Find Full Text PDFFungal infection in patients treated with Bruton's Tyrosine Kinase inhibitor, from epidemiology to clinical outcome: A systematic review.
Clin Microbiol Infect
December 2024
Sorbonne Université, CIMI-Paris, AP-HP, Service de Parasitologie-Mycologie, Hopital de La Pitie-Salpetriere, F-75013 Paris, France. Electronic address:
Background: Bruton Tyrosine Kinase inhibitor (BTKi) emerged as key treatment for B-cell lymphomas. Despite its efficacy in the treatment of malignancies, numerous cases of invasive fungal infections (IFI) have been reported in patients receiving ibrutinib, a first generation BTKi. Cases of invasive aspergillosis have also been reported with acalabrutinib and zanubrutinib.
View Article and Find Full Text PDFGenome-Wide Exploration of Thiamin Pyrophosphate Riboswitches in Medically Relevant Fungi Reveals Diverse Distribution and Implications for Antimicrobial Drug Targeting.
ACS Omega
December 2024
Laboratory for Applied Genomics and Bioinnovations, Oswaldo Cruz Institute (IOC - FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
The rising incidence of fungal infections coupled with limited treatment options underscores the urgent need for novel antifungal therapies. Riboswitches, particularly thiamin pyrophosphate (TPP) class, have emerged as promising antimicrobial targets. This study presents a comprehensive genome-wide analysis of TPP riboswitches in 156 medically relevant fungi utilizing advanced covariance models (CMs) tailored for fungal sequences.
View Article and Find Full Text PDFCT imaging findings of invasive pulmonary fungal infections in hemato-oncologic children.
Insights Imaging
December 2024
Department of Radiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Hemato-oncologic children form a heterogeneous group with a wide spectrum of ages, malignancy types, and immunosuppression grades during the different phases of their treatment. Immunosuppression is caused by multiple factors, including the malignancy itself, bone marrow suppression secondary to therapy, and wide use of steroids and antibiotics, among others. At the same time, the risk of infections in these patients remains high because of prolonged hospitalizations or the need for long-timing implanted devices between other features.
View Article and Find Full Text PDFCAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections.
Open Forum Infect Dis
November 2024
Microbiology and Molecular Biology Laboratories, Department of Pathology, Westchester Medical Center, Valhalla, New York, USA.
The global burden of invasive fungal disease is substantial and escalating. Combination antifungal therapy (CAF) may improve patient outcomes by reducing development of resistance, improving drug penetration and rate of fungal clearance, and allowing for lower and less toxic antifungal drug doses; yet, increased cost, antagonism, drug-drug interactions, and toxicity are concerns. Clinical practice guidelines recommend antifungal monotherapy, rather than CAF, for most invasive fungal diseases due to a lack of comparative randomized clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!